259 related articles for article (PubMed ID: 23615785)
1. Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.
Møller P; Stormorken A; Jonsrud C; Holmen MM; Hagen AI; Clark N; Vabø A; Sun P; Narod SA; Mæhle L
Breast Cancer Res Treat; 2013 May; 139(1):155-61. PubMed ID: 23615785
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program.
Chiarelli AM; Prummel MV; Muradali D; Majpruz V; Horgan M; Carroll JC; Eisen A; Meschino WS; Shumak RS; Warner E; Rabeneck L
J Clin Oncol; 2014 Jul; 32(21):2224-30. PubMed ID: 24934793
[TBL] [Abstract][Full Text] [Related]
3. Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.
Hartman AR; Daniel BL; Kurian AW; Mills MA; Nowels KW; Dirbas FM; Kingham KE; Chun NM; Herfkens RJ; Ford JM; Plevritis SK
Cancer; 2004 Feb; 100(3):479-89. PubMed ID: 14745863
[TBL] [Abstract][Full Text] [Related]
4. Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.
Obdeijn IM; Winter-Warnars GA; Mann RM; Hooning MJ; Hunink MG; Tilanus-Linthorst MM
Breast Cancer Res Treat; 2014 Apr; 144(3):577-82. PubMed ID: 24567197
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
[TBL] [Abstract][Full Text] [Related]
6. MRI screening in a clinic population with a family history of breast cancer.
Yu J; Park A; Morris E; Liberman L; Borgen PI; King TA
Ann Surg Oncol; 2008 Feb; 15(2):452-61. PubMed ID: 18026801
[TBL] [Abstract][Full Text] [Related]
7. Improvement in DCIS detection rates by MRI over time in a high-risk breast screening study.
Warner E; Causer PA; Wong JW; Wright FC; Jong RA; Hill KA; Messner SJ; Yaffe MJ; Narod SA; Plewes DB
Breast J; 2011; 17(1):9-17. PubMed ID: 21251121
[TBL] [Abstract][Full Text] [Related]
8. Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition.
Kriege M; Brekelmans CT; Boetes C; Muller SH; Zonderland HM; Obdeijn IM; Manoliu RA; Kok T; Rutgers EJ; de Koning HJ; Klijn JG;
Cancer; 2006 Jun; 106(11):2318-26. PubMed ID: 16615112
[TBL] [Abstract][Full Text] [Related]
9. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).
Leach MO; Boggis CR; Dixon AK; Easton DF; Eeles RA; Evans DG; Gilbert FJ; Griebsch I; Hoff RJ; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Thompson D; Warren RM;
Lancet; 2005 May 21-27; 365(9473):1769-78. PubMed ID: 15910949
[TBL] [Abstract][Full Text] [Related]
10. Mammographic, US, and MR imaging phenotypes of familial breast cancer.
Schrading S; Kuhl CK
Radiology; 2008 Jan; 246(1):58-70. PubMed ID: 18096529
[TBL] [Abstract][Full Text] [Related]
11. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series.
Hagen AI; Kvistad KA; Maehle L; Holmen MM; Aase H; Styr B; Vabø A; Apold J; Skaane P; Møller P
Breast; 2007 Aug; 16(4):367-74. PubMed ID: 17317184
[TBL] [Abstract][Full Text] [Related]
14. Balancing sensitivity and specificity: sixteen year's of experience from the mammography screening programme in Copenhagen, Denmark.
Utzon-Frank N; Vejborg I; von Euler-Chelpin M; Lynge E
Cancer Epidemiol; 2011 Oct; 35(5):393-8. PubMed ID: 21239242
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
[TBL] [Abstract][Full Text] [Related]
16. Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).
Saadatmand S; Obdeijn IM; Rutgers EJ; Oosterwijk JC; Tollenaar RA; Woldringh GH; Bergers E; Verhoef C; Heijnsdijk EA; Hooning MJ; de Koning HJ; Tilanus-Linthorst MM
Int J Cancer; 2015 Oct; 137(7):1729-38. PubMed ID: 25820931
[TBL] [Abstract][Full Text] [Related]
17. MRI of the breast as part of the assessment in population-based mammography screening.
Bick U; Engelken F; Diederichs G; Dzyuballa R; Ortmann M; Fallenberg EM
Rofo; 2013 Sep; 185(9):849-56. PubMed ID: 23740312
[TBL] [Abstract][Full Text] [Related]
18. The development of interval breast malignancies in patients with BRCA mutations.
Komenaka IK; Ditkoff BA; Joseph KA; Russo D; Gorroochurn P; Ward M; Horowitz E; El-Tamer MB; Schnabel FR
Cancer; 2004 May; 100(10):2079-83. PubMed ID: 15139048
[TBL] [Abstract][Full Text] [Related]
19. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
Warner E; Plewes DB; Hill KA; Causer PA; Zubovits JT; Jong RA; Cutrara MR; DeBoer G; Yaffe MJ; Messner SJ; Meschino WS; Piron CA; Narod SA
JAMA; 2004 Sep; 292(11):1317-25. PubMed ID: 15367553
[TBL] [Abstract][Full Text] [Related]
20. Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
Podo F; Santoro F; Di Leo G; Manoukian S; de Giacomi C; Corcione S; Cortesi L; Carbonaro LA; Trimboli RM; Cilotti A; Preda L; Bonanni B; Pensabene M; Martincich L; Savarese A; Contegiacomo A; Sardanelli F
Clin Cancer Res; 2016 Feb; 22(4):895-904. PubMed ID: 26503945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
